---
title: "Novo Nordisk AS will lay off 11% of its global workforce and again lower its profit growth expectations"
description: "Novo Nordisk announced that it will lay off 11% of its global workforce, or 9,000 people, and has lowered its full-year profit growth forecast for the third time. The company expects to save DKK 8 bil"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/256675572.md"
published_at: "2025-09-10T06:18:41.000Z"
---

# Novo Nordisk AS will lay off 11% of its global workforce and again lower its profit growth expectations

> Novo Nordisk announced that it will lay off 11% of its global workforce, or 9,000 people, and has lowered its full-year profit growth forecast for the third time. The company expects to save DKK 8 billion by the end of 2026 through these layoffs, which will affect employees including 5,000 Danish staff. At constant exchange rates, the full-year operating profit is expected to grow by 4% to 10%, down from the previous forecast of 27%. The layoffs are part of the company's transformation plan aimed at streamlining its organizational structure and enhancing performance culture

Novo Nordisk will lay off 9,000 employees globally and has lowered its full-year profit forecast for the third time. The company is striving to address the challenges posed by declining performance. The Danish pharmaceutical company aims to save DKK 8 billion by 2026 through these layoffs, which will affect 11% of its workforce, including 5,000 employees in Denmark. Novo Nordisk stated that operating profit for the full year, calculated at constant exchange rates, will grow by 4% to 10%. The company had predicted in February that profit growth could reach as high as 27%. Novo Nordisk mentioned that it will communicate with the affected employees in the coming months. The layoffs announced on Wednesday are part of the company's transformation plan aimed at streamlining the organizational structure, improving decision-making speed, and reallocating resources towards growth areas such as diabetes and obesity treatment

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Puzo Michael J 在诺和诺德公司 $NVO 拥有价值 32 万美元的股票持仓 | Puzo Michael J 在第三季度大幅减持了 Novo Nordisk A/S (NYSE:NVO) 的股份，减少幅度达到 86.9%，目前持有 5,775 股，价值 320,000 美元。其他机构投资者也调整了他们的持仓，True  | [Link](https://longbridge.com/en/news/276447697.md) |
| 诺和诺德公司董事会提议再次选举 Lars Rebien Sorensen 担任主席 | 诺和诺德公司董事会提议重新选举拉斯·瑞比恩·索伦森为董事长 | [Link](https://longbridge.com/en/news/276440991.md) |
| 特朗普暗示违法征收的关税不退了，美财长称今年关税收入将 “基本保持不变” | 美国总统特朗普暗示不会退还被最高法院裁定违法的关税，预计 2026 年关税收入将保持不变。特朗普计划签署行政令，对全球商品加征 10% 进口关税，取代被推翻的关税。财长贝森特表示，政府将利用替代法律权力维持关税收入，强调国家安全和财政收入不 | [Link](https://longbridge.com/en/news/276494362.md) |
| 最高法裁决后特朗普动用替补选择：加征 10% 全球关税 | 美国总统特朗普在最高法院裁决后宣布将加征 10% 的全球关税，以补救被推翻的关税措施。根据《1974 年贸易法》第 122 条款，现有的关税将全面生效。最高法院裁定特朗普政府的部分关税措施缺乏法律授权。市场风险提示，投资需谨慎。 | [Link](https://longbridge.com/en/news/276477629.md) |
| 高盛：诺和诺德定价压力被市场过度定价，口服 Wegovy 将是扭转信心的关键 | 高盛称，当前股价已完全消化 2026 财年最悲观预期。市场低估了 Medicare 放开的销量潜力和口服版 Wegovy 的收入前景。口服 Wegovy 上市表现强劲，已开出 5 万张处方，其中 9 成为自费需求，显示刚性市场潜力，将成为扭 | [Link](https://longbridge.com/en/news/275095024.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.